ALT Historical PE Ratio Notes

— Altimmune (ticker: ALT) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and liver diseases, including obesity & non-alcoholic steatohepatitis (NASH). Its lead candidate, pemvidutide, is designed to target both weight loss and liver health, aiming to disrupt large, growing markets. When reviewing historical PE ratios, keep in mind that ALT, like many biotech firms, often has little or no earnings during lengthy R&D phases, making its PE ratio either extremely high, undefined, or volatile. The absence of steady profits means the PE ratio, when it exists, reflects investor expectations about the future commercial potential of Altimmune's pipeline rather than current earnings power. Significant milestones such as positive clinical trial results, regulatory updates, or changes in competitive dynamics can trigger price spikes & sharp swings in the PE ratio. When looking at historical charts or tables, periods of negative or very low earnings can result in dramatic moves or gaps in the PE ratio data, so it's crucial to interpret those numbers in the context of the company's development stage rather than expecting the kind of steady PE trends you'd find in profitable, mature companies.

On this page we presented the ALT Historical PE Ratio information for Altimmune' stock. The average ALT historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ALT historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ALT historical PE result, against the recent PE: when this page was posted on 8/5/2026, the most recent closing price for ALT had been 3.03, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on ALT or any other given stock, valuation analysis for ALT can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Altimmune PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ALT. Thanks for visiting, and the next time you need to research ALT Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.